Yovision CFO Departs Amid IPO Preparations, Replaced by Nasus Pharma Executive

Yovision, an Israeli suicide drone company owned by Aharon Frandl, is facing challenges as it prepares for a Nasdaq IPO targeting a $3.5 billion pre-money valuation. During these preparations, CFO Roni Barak unexpectedly resigned under unclear circumstances. He will be replaced by Eyal Rubin, the current CFO of Nasdaq-traded Nasus Pharma, who recently announced his planned departure in September.

Yovision's valuation efforts have been complicated by a downturn in defense sector stocks, to which the company belongs. For example, Next Vision's shares on the Tel Aviv Stock Exchange have dropped about 40% since their peak in early March, now valued at approximately 20 billion shekels. Frandl initially sought to bring Israeli institutional investors into 5%-10% of Yovision, but they valued the company at only $2.5 to $2.9 billion, below his target. After two years of strong gains, defense stocks have declined, making it difficult for Frandl to secure even that lower valuation from institutional investors.

Although the IPO is planned for the U.S., Yovision began its roadshow about a month ago in Israel with local institutional investors. Due to the valuation challenges, Frandl may need to lower his price expectations to complete the offering this year, after initially aiming for a summer IPO. The CFO change occurs amid these ongoing efforts to finalize the public listing.

Summary: Yovision's CFO Roni Barak resigned amid preparations for a Nasdaq IPO targeting a $3.5 billion valuation, with Eyal Rubin set to replace him. The company faces valuation difficulties due to a decline in defense stocks and investor resistance, potentially forcing a lower IPO price to complete the offering this year.